Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aubagio

- PMLiVE

Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

- PMLiVE

Tiziana shares promising results for intranasal foralumab in multiple sclerosis

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer

Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024

- PMLiVE

Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia

The late-stage LUNA 3 study results will be presented at a medical congress later this year

- PMLiVE

J&J and Legend’s Carvykti receives EC approval to treat relapsed and refractory multiple myeloma

The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse

- PMLiVE

Astellas announces EC approval of Xtandi for expanded prostate cancer use

Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years

- PMLiVE

AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH

The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

- PMLiVE

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

The chronic neurological condition affects more than 2.8 million people worldwide

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

EU flag

European Parliament approves pharma reform compromise for equal access to new medicines

The new proposal will be finalised after the EU elections take place in June 2024

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links